Dr. Mark Souweidane, a neurosurgeon at Memorial Sloan Kettering and the Director of the Weill Cornell Pediatric Brain and Spine Center, officially received FDA approval on Thursday, December 29, 2011 for his pioneering clinical trial aimed at finding a cure for Diffuse Intrinsic Pontine Glioma. Dr. Souweidane will be selecting 12 patients for the trial, which is expected to begin in the last week of January. The innovative use of convection-enhanced delivery (CED) will be the first of its kind to administer radio immunotherapy to children with an otherwise incurable tumor. The doctor has worked for the past 12 years to cure the inoperable tumor, which takes the life of 200 children in the United States every year, typically within three to 18 months after diagnosis.
Friday, December 30, 2011
FDA Officially Approves Clinical Trial Headed By Dr. Mark Souweidane
Dr. Mark Souweidane, a neurosurgeon at Memorial Sloan Kettering and the Director of the Weill Cornell Pediatric Brain and Spine Center, officially received FDA approval on Thursday, December 29, 2011 for his pioneering clinical trial aimed at finding a cure for Diffuse Intrinsic Pontine Glioma. Dr. Souweidane will be selecting 12 patients for the trial, which is expected to begin in the last week of January. The innovative use of convection-enhanced delivery (CED) will be the first of its kind to administer radio immunotherapy to children with an otherwise incurable tumor. The doctor has worked for the past 12 years to cure the inoperable tumor, which takes the life of 200 children in the United States every year, typically within three to 18 months after diagnosis.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment